Editorial: Refractory Pituitary Adenoma-Current Challenges and Emerging Treatments.

Wang, Renzhi; Zhou, Cuiqi; McCormack, Ann I; Mamelak, Adam N

Wang, Renzhi; Zhou, Cuiqi; McCormack, Ann I; Mamelak, Adam N.

Afiliação

Wang R; Department of Neurosurgery, Peking Union Medical College Hospital (CAMS), Beijing, China.
Zhou C; Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, United States.
McCormack AI; Department of Endocrinology, St Vincent's Hospital Sydney, Darlinghurst, NSW, Australia.
Mamelak AN; Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, CA, United States.

Front Endocrinol (Lausanne) ; 13: 868174, 2022.

Article em En | MEDLINE | ID: mdl-35355554

Palavras-chave

diagnosis; drug resistance; medical therapy; pathogenesis; refractory pituitary adenomas; surgical treatment; temozolomide, targeted and immunotherapy

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Front Endocrinol (Lausanne) Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Front Endocrinol (Lausanne) Ano de publicação: 2022 Tipo de documento: Article